The financial media tends to ignore this fact: Some of the world’s richest people became rich from a single stock investment.
Instead, the talking heads drive investors to think the only way to riches is to buy index funds, then pray your savings and rate of return can get you to retirement.
But than one-flavor financial plan isn’t the only path.
Look at the world’s richest people. None of them made a fortune by diversifying into hundreds of stocks.
No, they became rich by concentrating their money into one stock they understood best.
Jeff Bezos got rich not by holding hundreds of stocks in a diversified account, but by concentrating his capital in the one stock he knew would succeed – Amazon.
Bill Gates did the same with Microsoft. Sam Walton did it with Wal-Mart. Steve Jobs did it with Apple. And Larry Page did the same with Google.
I know you might be thinking, “These are the founders of those companies.” That’s true.
But shareholders made a fortune right alongside them. And that possibility is available to you too… All you have to do is find the right stocks and act.
In this report, we outline five stocks that have the potential to hand you a retirement fortune. It’s possible that one of these little-known stocks could be the next Apple, Amazon or Google.
But first, we’ll outline the key elements required in retirement-changing stocks.
Key Elements of Retirement-Changing Stocks
If you jumped into a time machine and headed to the past, you would notice that today’s Wall Street darlings shared specific traits.
And finding those traits amongst today’s lesser-known stocks is how you unlock a potential fortune.
Key elements they shared include:
· Cutting-edge technologies or services that disrupted their industries
· Massive sales growth that was projected to increase dramatically
· Just becoming profitable or expected to become profitable in the next 12 months
· Not well-known or substantially covered by the financial media
· Traded for a few dollars a share.
The last element is key. If you are going to take a small investment and turn it into a dream retirement portfolio, you have to get in early.
To do this, you must target microcap stocks. The lower price of these stocks allows you to maximize your per share investment.
For example, Cray Inc. (Nasdaq: CRAY) was a low-priced stock back in November 2008. It traded for $1.37 a share and also embodied the other four elements of a retirement-changing stock.
The company was on the cutting edge of data management and supercomputing, experienced triple-digit sales growth, turned a profit for the first time in five years and wasn’t getting any love from the mainstream financial press.
Had you picked up shares back in late 2008, your small investment would have grown 2,995.62% by 2016.
And some retirement-changing stocks can see the same massive price movements in shorter periods of time.
Take AXT Inc. (Nasdaq: AXTI), for example. The pioneering semiconductor company possessed the same key traits as Cray back in 2008. And remember, this was when the financial markets were melting down.
Had you picked up AXT for just $0.95 a share, two years later, your shares would have been worth $10.44 apiece. That’s a 944% gain, something large cap stocks can’t hand you in such a short time frame.
Real retirement-changing ten-baggers (companies poised for 10X returns) like Cray and AXT are out there. But you have to sift through the universe of today’s stocks and spot the potential winners with the five key traits.
And in this report, we’ve done the research for you. We’ve uncovered five stocks that could forever transform your retirement portfolio.
No. 1 Retirement-Changing Stock: Senseonics Holdings Inc. (NYSE: SENS)
Founded in 1996, Senseonics (NYSE: SENS) is a medical technology company that has developed a long-term, implantable continuous glucose monitoring (or CGM) to help patients manage their disease with relative ease and accuracy.
Its CGM systems are designed to continually and accurately measure glucose levels using an under-the-skin sensor, a removable and rechargeable smart
transmitter and a convenient app for real-time monitoring and management.
The company’s original Eversense CGM system was approved by the U.S. Food and Drug Administration in 2018, then for a non-adjunctive indication in 2019. That sets up its Eversense CGM system as the premier replacement for fingerstick blood glucose measurements.
Earnings per share are expected to rise as much as 80% next year, and by an average of 32% over the next five years. With excellent growth prospects, the stock is incredibly cheap these days. And after a brief dip in sales due to the pandemic’s impact on the industry in 2020, its set to come roaring back in the months and years ahead.
No. 2 Retirement- MannKind Corp. (Nasdaq: MNKD)
MannKind Corp. (Nasdaq: MNKD) is a biopharmaceutical company focused on inhaled therapeutic products for endocrine and orphan lung diseases. The company’s lead product is Afrezza Inhalation Powder, which is an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, which was approved by the FDA in June 2014.
The company is also working with United Therapeutics to develop another inhaled insulin formulation, known as Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. It reached a major milestone in June 2020 with the announcement that the FDA accepted for priority review of the New Drug Application (NDA) for Tyvaso DPI.
Earnings per share are forecasted to grow 38% next year, and by an average of 36% over the next five years. The stock’s not only cheap based on its market price, but also compared to its peers. With a price-to-cash ratio of just 4, its one of the cheaper, yet, very promising, biopharmaceutical companies in the industry, which generally trade at far greater multiples over their cash holdings.
No. 3 Retirement-Changing Stock: Antares Pharma (Nasdaq: ATRS)
Antares Pharma, Inc. (Nasdaq: ATRS) is a specialty pharmaceutical company focused primarily on pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It works alongside industry leading pharmaceutical companies including Pfizer Inc. (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA).
One of its flagship products is its XYOSTED® injection, which is a testosterone replacement therapy for adult males with conditions associated with a testosterone deficiency. It is the only FDA approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration, and was approved in late 2018.
It has also developed OTREXUP, which is a subcutaneous methotrexate injection for once weekly self-administration with an easy-to-use, single dose, disposable auto injector, indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis.
Earnings per share are expected to rise by a phenomenal 130% next year. Yet its still trading at an incredible low price. So grab some shares while this one’s still under the radar.
No. 4 Retirement-Changing Stock: Siebert Financial Corp. (Nasdaq: SIEB)
Based in New York City, Siebert Financial Corp. (Nasdaq: SIEB) is a discount brokerage and investment advisor with more than $11 billion in assets under management. The firm has 11 branch offices and has been in business for more than 50 years.
It is named after Muriel Faye Siebert, often referred to as “the first woman of finance.” In 1967, she became the first woman to obtain a seat on the New York Stock Exchange.
The controlling shareholder today is board member Gloria Gebbia, who owns more than 10 million shares. Indeed, insiders – including other Gebbia family members – own 93.7% of the outstanding shares here. In the past, Gloria Gebbia made no secret that – with 10 grandchildren – she would like to keep the company in the family.
So there is a possibility that she could buy the other shareholders out. Or the firm might put itself up for sale to the highest bidder. I consider this a stronger probability. After all, there is a lot of consolidation going on in the discount brokerage industry.
Charles Schwab recently bought TD Ameritrade for $26 billion. Then Morgan Stanley agreed to buy E-Trade for $13 billion. Siebert Financial is just a minnow by comparison.
With a market cap of just $136 million, even a small brokerage firm could expand by purchasing the firm. And with $11 billion in assets under management, why wouldn’t they?
The top line at Siebert is growing at a 23% annual rate. But earnings have been falling. A buyout could quickly change that.
In an increasingly competitive world, where large companies have economies of scale that smaller players can’t match, it would make sense to sell. I consider it just a matter of time before Siebert hits the auction block. And at a substantial premium to today’s market price.
No. 5 Retirement-Changing Stock: Exicure (Nasdaq: XCUR)
Based outside of Chicago and in Cambridge, Massachusetts, Exicure (Nasdaq: XCUR)
is a clinical-stage biotechnology company developing new therapies for inflammatory diseases and genetic disorders. It is also a pioneer in immunotherapeutic drugs.
Industry analysts estimate that in less than a decade, immune-based treatments will generate up to $70 billion a year in sales. That will make them the most valuable class of drugs in history.
Epicure has a broad pipeline of therapeutics to treat a broad range of diseases with great unmet medical needs. Like many development-stage companies, Epicure is not yet profitable. However, it generated nearly a million dollars of revenue last tear. And, while the firm will not be profitable this year, revenue should rise to more than $1.5 billion this year. As Epicure gets closer to profitability, the stock should gap higher. There is also a strong buyout possibility. One person who agrees with this analysis is Dr. Bali Muralidhar, a member of the board of directors. Muralidhar has more than 15 years’ experience in the healthcare industry and is also a partner at Abingworth LLP, an investment firm specializing in life science companies.
But Muralidhar made a public statement when he was appointed to the board last year:
Exicure has developed a new class of genetic medicines with a differentiated platform for oligonucleotide drugs… I am pleased to be joining the board during this important time and to work with such a high-quality team. Abingworth is delighted to have led Exicure’s recent oversubscribed financing, which will help enable the company to advance its rich pipeline of development candidates and bring much-needed therapies to unserved patients globally.
Today you can buy the stock cheaper than Muralidhar did. And you should.
Our Favorite Stock Trading Under $6
We believe the five stocks above have the potential to change your retirement for good. All have the same fundamental elements of past winning stocks.
But if you are looking for the one stock to invest in first, it isn’t on our list above…
You see, our Chief Investment Strategist, Alexander Green, just uncovered what he believes is the perfect stock. And you’ve likely never heard of it. Why? Because it trades under a secret name.
You can check out his first-ever “Tek Talk” for details regarding this perfect stock.
But you must act now.
A huge announcement involving Trump and America’s No. 1 tech company is about to bring this secret $6 stock into the light. Click here now to see more for yourself.
Good investing,
Kristin OrmanDirector of Research
Liberty Through Wealth
Updated 6/25/2021